<DOC>
	<DOCNO>NCT02516436</DOCNO>
	<brief_summary>A randomized , double blind , active control study approximately 40 opioid dependent subject . Study duration five day include maximum 3 day confinement clinic . Opioid dependent subject provide inform consent meet entry criterion eligible enrollment study .</brief_summary>
	<brief_title>The Safety Using Buprenorphine With Naloxone Buccal Film Initiate Treatment Opioid Dependent Subjects</brief_title>
	<detailed_description>A randomized , double blind , active control study approximately 40 opioid dependent subject . The study include Screening period 3 day 2-day , double blind induction phase ( subject confine clinic ) . Screening first day treatment ( Day 1 ) may occur day Screening may occur 3 day prior Day 1 . Opioid dependent subject provide inform consent Screening visit ; Clinical Opiate Withdrawal Scale ( COWS ) total score ≥12 ; meet entry criterion eligible enrollment study . Subjects confine clinic beginning Day 1 ( optional confinement Day -1 ) remain 48 hour administration first study drug dose .</detailed_description>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>1 . Signed informed consent obtain prior study procedure perform 2 . Prespecified plan continue treatment follow study participation 3 . Male nonpregnant nonnursing female . A female childbearing potential eligible participate study pregnant use acceptable method birth control . 4 . Subject age 18 55 year , inclusive 5 . Current diagnosis opioid substance use disorder per Diagnostic Statistical Manual Mental Disorders 5th edition ( DSM5 ) 6 . Clinical opioid withdrawal scale ( COWS ) total score ≥12 prior dose Day 1 7 . Subject otherwise good general health judgment Investigator determine physical oral examination finding . 8 . Subject commit get help opioid dependence , judgment Investigator . 9 . Subject least 1 verified contact . 1 . Inability meet study participation requirement , include stay 2 night clinic 2 . Positive buprenorphine methadone result urine drug screen Screening Baseline 3 . Concurrent Diagnostic Statistical Manual Mental Disorders 5th edition diagnosis substance use disorder ( exclude opioids tobacco ) 4 . Prolonged QT interval medical history , family history , current electrocardiogram ( ECG ) find 5 . History clinically significant hepatic impairment determine Investigator . 6 . Use medication , nutraceutical herbal product CYP3A4 inhibition induction property within past 30 day . This exclusion also extend grapefruit juice grapefruit juicecontaining product well St. John 's wort St. John 's wortcontaining product ( prescription nonprescription drug , vitamin , mineral , dietary/herbal supplement ) . 7 . Use investigational drug device within last 30 day 8 . History hypersensitivity , allergy , intolerance buprenorphine naloxone 9 . Increased suicidal risk , determine meeting follow : History suicidal ideation ≤ 3 month prior Baseline score 4 ( intent act ) 5 ( specific plan intent ) electronic Columbia Suicide Severity Rating Scale ( eCSSRS ) History suicidal behavior ≤1 year prior Baseline ( actual attempt , interrupt attempt , abort attempt and/or preparatory acts/behavior ) electronic Columbia Suicide Severity Rating Scale ( eCSSRS ) 10 . Lack motivation pattern prior poor response treatment , judge investigator 11 . A history current evidence clinically significant disorder condition opinion Investigator , would jeopardize safety subject impact validity study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Bunavail</keyword>
	<keyword>Suboxone</keyword>
	<keyword>Heroin</keyword>
	<keyword>Zubsolv</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Naloxone</keyword>
	<keyword>Opioids</keyword>
	<keyword>Addiction</keyword>
	<keyword>Induction</keyword>
</DOC>